PTGX
Protagonist Therapeutics, Inc
Key Financials
Revenue
$8.8M
N/A
Net Income
$-130149000
↓ 147.3%
Operating Income
$-158127000
↓ 162.5%
EPS (Diluted)
$-2.05
↓ 148.5%
Total Liabilities
$53.5M
↓ 23.0%
Total Assets
$668.2M
↓ 10.3%
Shareholders' Equity
$614.7M
↓ 9.0%
Long-term Debt
$9.8M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4/A | 5/14/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 144 | 5/12/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
| 144 | 5/8/2026 | View on SEC |
| 144 | 5/7/2026 | View on SEC |
| 144 | 5/7/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PTGX |
| Company Name | Protagonist Therapeutics, Inc |
| CIK | 1377121 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (510) 474-0170 |